Please provide your email address to receive an email when new articles are posted on . Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 ...

Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...

The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than ...

Boston, MA — December 18, 2025 — A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around ...

Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic ...

There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...

BOSTON — In a preliminary study of men with type 2 diabetes, the use of phosphodiesterase type-5 (PDE5) inhibitors was associated with reduced all-cause mortality, even in men who had a previous ...

Use of a phosphodiesterase type-5 (PDE5) inhibitor was associated with a lower risk for death and cardiovascular events than alprostadil for the treatment of erectile dysfunction in men with stable ...

Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.